| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 4004 |
Provisional Schedule
| Expected publication | 15 January 2025 |
Project Team
| Project lead | Vonda Murray |
Email enquiries
- If you have any queries please email tateam3@nice.org.uk
Stakeholders
| Companies sponsors | Pfizer |
| Others | Department of Health and Social Care |
| NHS England | |
| Heath Technology Wales | |
| Patient carer groups | Black Health Agency for Equality |
| Bob Champion Cancer Trust | |
| Cancer Black Care | |
| Cancer Equality | |
| Caribbean and African Health Network | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Macmillan Cancer Support | |
| Maggie's Centres | |
| Marie Curie | |
| Orchid | |
| PCaSO - Prostate Cancer Support Organisation | |
| Pelican Cancer Foundation | |
| Prost8 UK | |
| Prostate Cancer Research | |
| Prostate Cancer UK | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tackle Prostate Cancer | |
| Tenovus Cancer Care | |
| Professional groups | Association of Anaesthetists |
| Association of Cancer Physicians | |
| Association of Surgeons of Great Britain and Ireland | |
| British Association of Urological Nurses | |
| British Association of Urological Surgeons | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Oncology Pharmacy Association | |
| British Psychosocial Oncology Society | |
| British Society of Urogenital Radiology | |
| British Uro-Oncology Group | |
| Cancer Research UK | |
| Prostate Cancer Advisory group | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal College of Surgeons of England | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society | |
| Urology Foundation | |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Accord (abiraterone) |
| Aristo Pharma (abiraterone) | |
| Astellas Pharma (enzalutamide) | |
| AstraZeneca (olaparib) | |
| Axunio Pharma (abiraterone, olaparib) | |
| Celix Pharma (abiraterone) | |
| Cipla (abiraterone) | |
| Dr. Reddy's Laboratories (abiraterone) | |
| Genus Pharmaceuticals (abiraterone) | |
| Janssen (abiraterone) | |
| Krka (abiraterone) | |
| Ranbaxy (abiraterone) | |
| Sandoz (abiraterone) | |
| Teva (abiraterone) | |
| Tillomed Laboratories (abiraterone) | |
| Torrent Pharma (abiraterone) | |
| Viatris UK Healthcare (abiraterone) | |
| Wockhardt UK (abiraterone) | |
| Evidence review group | Peninsula Technology Assessment Group (PenTAG) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| National Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane UK |
| Cochrane Urology | |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Institute for Health Research | |
| Pro Cancer Research Fund |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2024 | Invitation to participate |
| 17 June 2024 - 01 July 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 June 2024 | In progress. In progress |
| 23 August 2023 | Suspended. Please note the company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps. |
| 31 July 2023 - 04 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1234 |
| 10 July 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early September 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 04 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes. |
| 02 September 2022 - 30 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 02 September 2022 | In progress. Scoping commenced |
| 05 August 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late November 2022. |
| 12 April 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual